Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avastin Breast Cancer Approval In Spotlight With AVADO

This article was originally published in The Pink Sheet Daily

Executive Summary

CHICAGO - First placebo-controlled, double-blinded evidence for bevacizumab in first-line metastatic breast cancer presented at ASCO.

You may also be interested in...



Genentech’s Sigh Of Relief: RIBBON-1 Trial Supports Avastin Use In Breast Cancer

Third study to show progression-free survival in metastatic breast cancer puts the company closer to full approval, and data on new combinations could expand the market.

Genentech’s Sigh Of Relief: RIBBON-1 Trial Supports Avastin Use In Breast Cancer

Third study to show progression-free survival in metastatic breast cancer puts the company closer to full approval, and data on new combinations could expand the market.

Avastin/Tarceva Combo Fails In Second-Line NSCLC

Industry analysts see little consequence, as each is already well-positioned in lung cancer.

Related Content

Topics

UsernamePublicRestriction

Register

OM002075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel